An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates

This publication has 13 references indexed in Scilit:

• Characterization of the Aqueous Decomposition Products of (+)1,2-bis(3,5-Dioxopiperazinyl-1-yl)-propane (ICRF-187) by Liquid Chromatographic and Mass Spectral Analysis
  Journal of Pharmaceutical Sciences, 1991
• Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction
  Cancer Treatment Reviews, 1991
• The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)
  Inflammation Research, 1990
• The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin
  Inflammation Research, 1989
• Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer
  New England Journal of Medicine, 1988
• Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex
  Biochemical Pharmacology, 1984
• Destruction of Phosphilipids and Respiratory‐Chain Activity in Pig=Heart Submitochondrial Particles Induced by an Adriamycin‐Iron Complex
  European Journal of Biochemistry, 1983
• Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex
  Biochemistry, 1982
• Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192
  Inflammation Research, 1982
• Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells
  Biochemical Pharmacology, 1975